• To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (pfizermedicalinformation.com)
  • Aztreonam for Injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. (pfizermedicalinformation.com)
  • Aztreonam for Injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. (pfizermedicalinformation.com)
  • Concurrent initial therapy with other antimicrobial agents and aztreonam for injection is recommended before the causative organism(s) is known in seriously ill patients who are also at risk of having an infection due to Gram-positive aerobic pathogens. (pfizermedicalinformation.com)
  • Aztreonam for Injection may be administered intravenously or by intramuscular injection. (pfizermedicalinformation.com)
  • 0.25mg ( 20 ml vial ) , injection solution for 1.48 bupivacaine hydrochloride inj. (tendersinmadhyapradesh.com)
  • 64.5mg / ml 30ml vial ( ) , injection solution for 1.85 chloroquine ( phosphate ) , syrup 1.86 chlorpheniramine maleate ( 4mg ) , tablet 1.87 chlorpromazine hydrochloride sugar coated tab ( 100 mg ) , tablet 1.88 chlorpromazine hydrochloride ( 25 mg ) , tablet 1.89 chlorpromazine hydrochloride ( 50 mg tab ) , tablet 1.9 chlorpromazine inj ip ( 25mg / ml ( 2ml amp ) ) , injection solution for 1.91 cholecalciferol concentrate ( powder form ) ph.eur. (tendersinmadhyapradesh.com)
  • 1 mg / ml ( ) , injection solution for 2.57 epirubicin ( 10mg vial ) , injection 2.58 epirubicin ( 50mg vial ) , injection 2.59 equine anti rabies immunoglobulin, ( not less than 300iu / ml ) , injection 2.6 erythromycin stearate tab 250 mg 2.61 erythromycin stearate ( 500 mg ) , tablet 2.62 erythropoietin ( 4000 iu inj vial ) , injection 2.63 ethinyl estriadiol+norethisterone tab ( 35 mcg +1mg ) , tablet 2.64 etiophylline and theophylline ( paediatric ) , syrup 2.65 etiophylline theophylline sr tab. (tendersinmadhyapradesh.com)
  • aztreonam decreases effects of BCG vaccine live by pharmacodynamic antagonism. (medscape.com)
  • aztreonam decreases effects of microbiota oral by pharmacodynamic antagonism. (medscape.com)
  • aztreonam decreases effects of typhoid vaccine live by pharmacodynamic antagonism. (medscape.com)
  • Certain antibiotics (eg, cefoxitin, imipenem) may induce high levels of beta-lactamase in vitro in some Gram-negative aerobes such as Enterobacter and Pseudomonas species, resulting in antagonism to many beta-lactam antibiotics including aztreonam. (pfizermedicalinformation.com)
  • It is available in multiple dosage forms (eg, solution for nebulization, metered-dose inhaler, PO solution). (medscape.com)
  • Vitamin deficiency may result from an inadequate diet, increased requirements (eg, pregnancy, lactation), or secondary to disease or drug use. (medscape.com)
  • After identical single intravenous or intramuscular doses of aztreonam for injection, the serum concentrations of aztreonam are comparable at 1 hour (1.5 hours from start of intravenous infusion) with similar slopes of serum concentrations thereafter. (nih.gov)
  • When aztreonam pharmacokinetics were assessed for adult and pediatric patients, they were found to be comparable (down to 9 months old). (nih.gov)
  • The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2) in subjects with normal renal function, independent of the dose and route of administration. (nih.gov)
  • In elderly patients, the mean serum half-life of aztreonam increased and the renal clearance decreased, consistent with the age-related decrease in creatinine clearance. (nih.gov)
  • aztreonam will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. (medscape.com)
  • METHODS: We conducted a literature review of clinical trials and case series, published from 1983 to 2017, reporting treatment efficacy results following administration of 1 g aztreonam intramuscularly or IV for uncomplicated gonococcal infections. (cdc.gov)
  • Aztreonam had an efficacy of 98.6% (95% CI: 97.5%-99.4%) for urogenital, 94.7% (95% CI: 82.3%-99.4%) for rectal and 81.3% (95% CI: 54.4%-96.0%) for pharyngeal gonococcal infections. (cdc.gov)
  • however, systemic absorption of aztreonam following inhaled administration is expected to be minimal. (rxlist.com)